Respiratory Disease News and Research

RSS

ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation's Choosing Wisely® campaign, was produced by a collaborative task force assembled by the American Thoracic Society (ATS) and the American College of Chest Physicians (ACCP).

30 Oct 2013

New study finds association between OSA and subclinical myocardial injury

Obstructive sleep apnea is known to be associated with an increased incidence of cardiovascular disease. Now a new study indicates that OSA is associated with subclinical myocardial injury, as indicated by increased high sensitivity troponin T levels. Elevated hs-TnT levels are predictive of both coronary heart disease and heart failure in the general population.

25 Oct 2013

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Distinguishing pertussis (also known as whooping cough) from other respiratory illnesses is challenging in particular among adults because the signs and symptoms of pertussis overlap with those of other respiratory diseases.

24 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program.

17 Oct 2013

New method to display viral DNA in host cells at single-molecule resolution

The medical, humanitarian and economical impact of viral diseases is devastating to humans and livestock. There are no adequate therapies available against most viral diseases, largely because the mechanisms by which viruses infect cells are poorly known.

17 Oct 2013

Researchers receive grant to improve outcomes for preterm infants who struggle to take first breaths

Monash University researchers have received a prestigious National Institutes of Health (NIH) project grant to find ways to improve outcomes for very preterm infants who struggle to take their first breaths.

10 Oct 2013

Study finds association between heart failure and air pollution

Air pollution increases heart attacks, according to research presented at the Acute Cardiac Care Congress 2013 by Dr Savina Nodari from Brescia, Italy.

7 Oct 2013

NIH awards 10 new grants to support genomics research in Africa

The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next four years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program

2 Oct 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Sigma-Tau Pharmasource, Aradigm Ink Manufacturing Deal For Respiratory Disease Treatment

...

16 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

People with severe asthma are less likely to respond to treatment

Barcelona, Spain: People with severe asthma, who are often described as 'steroid-dependent', are actually less likely to respond to the treatment they depend on, when compared to people with mild asthma.

10 Sep 2013

Study confirms exposure to arsenic in drinking water can impair lung function

A new study confirms that exposure to low to moderate amounts of arsenic in drinking water can impair lung function. Doses of about 120 parts per billion of arsenic in well water-about 12 times the dose generally considered safe-produced lung damage comparable to decades of smoking tobacco. Smoking, especially by males, made arsenic-related damage even worse.

23 Aug 2013

Investigators link acute viral infections to development of COPD

Investigators at Washington University School of Medicine in St. Louis have described another link in the chain of events that connect acute viral infections to the development of chronic obstructive pulmonary disease (COPD).

16 Aug 2013

Burning incense generates indoor air pollutants that may cause inflammation in human lung cells

Burning incense, a popular cultural practice in Arabian Gulf countries and elsewhere, generates indoor air pollutants that may cause inflammation in human lung cells, say researchers in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

3 Aug 2013

ATS releases clinical practice guidelines on management of childhood ILD in infants

The American Thoracic Society has released new clinical practice guidelines on the classification, evaluation and management of childhood interstitial lung disease in infants.

1 Aug 2013

Many women die due to Cad, yet less likely to receive preventive recommendations

Despite coronary artery disease (CAD) killing at least as many women as men each year, women are still today less likely to receive preventive recommendations, such as lipid-lowering therapy, aspirin, and lifestyle advice, than are men at a similar risk level.

29 Jul 2013

Study: COPD linked with increased risk of developing cerebral microbleeds

Chronic obstructive pulmonary disease is associated with an increased risk of developing cerebral microbleeds, according to a new study from researchers in the Netherlands. Cerebral microbleeds are a marker of cerebral small vessel disease, an important cause of age-related disability and cognitive decline.

19 Jul 2013